Lexaria Bioscience Corp. Warrant - LEXXW STOCK NEWS

Lexaria Bioscience Corp. announced positive results from its pulmonary hypertension clinical study, HYPER-H21-3, showing DehydraTECH-CBD significantly reduced pulmonary artery systolic pressure (PASP) in male participants. The treatment demonstrated a 41% overall reduction in PASP (p=0.045) during hypoxic conditions, supporting further research efforts. Lexaria intends to utilize these findings to seek FDA approval for formal clinical testing in hypertension management. The global hypertension market, valued at $28 billion, presents a significant opportunity for DehydraTECH-CBD as a potential treatment option.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a new human nicotine study, NIC-H22-1, set to commence this summer, involving a minimum of 36 participants. The double-blinded study aims to compare the performance of Lexaria's DehydraTECH-nicotine pouches against leading brands like ON! and Zyn, with a focus on pharmacokinetic data and subjective user experiences. Lexaria previously noted success in animal studies, showing a significant increase in nicotine absorption speed. The oral nicotine pouch market is projected to grow significantly, reaching $21.84 billion by 2027.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has launched its epilepsy research program, EPIL-A21-1, which will evaluate the effectiveness of DehydraTECH-CBD against Epidiolex, the first FDA-approved CBD treatment for seizures. The necessary test articles have been prepared and delivered to a third-party lab for dosing. Research phases will include acute and chronic seizure models, starting in May/June, with results expected by Q3 2022. The program is fully funded through existing resources, underscoring Lexaria's commitment to advancing its drug delivery technology.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the granting of its 24th patent, titled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof," enhancing its global intellectual property portfolio. This Australian patent allows the use of DehydraTECH technology for various nicotine forms, potentially increasing product value. Previous studies show DehydraTECH delivers nicotine significantly faster than conventional methods. Additionally, the company issued 36,700 stock options to staff at an exercise price of $3.39.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reported significant findings from an animal study evaluating its DehydraTECH formulation of sildenafil, showing a 74% increase in drug delivery at 4 minutes compared to a generic control. The study indicated a 70% higher maximum concentration (Cmax) and a 37% improvement in total delivery (AUC). Results showed potential for developing faster-acting sildenafil formulations. However, improvements did not achieve statistical significance, necessitating further studies.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) shared an annual letter from CEO Chris Bunka, highlighting successes and strategic directions for the company. The focus remains on advancing the DehydraTECH drug delivery technology, aimed at overcoming industry inertia and regulatory challenges. Lexaria reported a growth in shareholder base, with average shares owned by NOBO shareholders increasing by 216% in 2021. The company's institutional ownership has also surged, ranging between 9% and 16%. The aim is to leverage this momentum for potential regulatory and commercial success in 2022.

Lexaria Bioscience Corp. (NASDAQ:LEXX) recently highlighted a study demonstrating cannabinoids' potential to inhibit SARS-CoV-2 infection.

Dr. Richard van Breeman noted that oral delivery of cannabinoids is recommended over smoking or vaping for effectiveness.

Lexaria's DehydraTECH™ technology enhances cannabinoid delivery, with applications in therapeutic formulations.

The study found cannabinoid acids can block cellular entry of the virus, presenting significant implications for treatment strategies.

Lexaria holds a strong patent portfolio, with ongoing research into pharmaceutical applications.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has received early Independent Review Board approval for its DehydraTECH-CBD hypertension study, HYPER-H21-4, scheduled to begin dosing by April 2022. This study, funded through existing cash resources, aims to assess the treatment's efficacy in reducing blood pressure among 60 volunteers aged 45-70. The $28 billion hypertension market presents significant growth potential, especially in emerging economies. With a comprehensive analysis including blood pressure monitoring and brain imaging, Lexaria seeks to validate DehydraTECH-CBD as a promising anti-hypertensive therapy.